Voltage-gated ion channels (VGCs) are prime targets for the pharmaceutical industry, but drug profiling on VGCs is challenging, since drug interactions are confined to specific conformational channel states mediated by changes in transmembrane potential. Here we combined various optogenetic tools to develop dynamic, high-throughput drug profiling assays with defined light-step protocols to interrogate VGC states on a millisecond timescale. We show that such light-induced electrophysiology (LiEp) yields high-quality pharmacological data with exceptional screening windows for drugs acting on the major cardiac VGCs, including hNa v 1.5, hK v 1.5 and hERG. LiEp-based screening remained robust when using a variety of optogenetic actuators (ChR2, ChR2(H134R), CatCh, ChR2-EYFP-βArchT) and different types of organic (RH421, Di-4-ANBDQPQ, BeRST1) or genetic voltage sensors (QuasAr1). The tractability of LiEp allows a versatile and precise alternative to state-of-the-art VGC drug screening platforms such as automated electrophysiology or FLIPR readers.
Results
LiEp on hNa v 1.5 channels. The hNa v 1.5 channel is the most challenging cardiac channel in terms of optical screening due to its fast kinetics and marked state-dependency. A drug-binding assay must cope with the channel's millisecond activation and inactivation kinetics over a large voltage range (Fig. 1a, Suppl. Fig. S1a ). For rapid bi-directional transmembrane voltage control, we constructed an improved optogenetic tandem protein 13 combining ChR2 and ArchT (ChR2-EYFP-βArchT) to enable calibrated blue light-induced cell depolarization and yellow light-induced cell hyperpolarization (Suppl. Fig. S1b ). We chose undifferentiated NG108-15 cells as recipient cells since they have been successfully used in previous experiments for high expression of tandem proteins 13 and since they are devoid of endogenous fast voltage-gated currents ( Fig. 1b ; −0.40 ± 1.07 nA, N = 15). NG108-15 cells transfected with pSCN5A encoding the alpha subunit of the hNa v 1.5 channel clearly developed voltage-step induced sodium currents ( Fig. 1b ; −7.09 ± 4.75 nA, N = 56, p < 0.0001). To determine the voltage-range of hNa v 1.5 activity in physiological solution, that is the voltage range that needs to be modulated by optogenetic membrane potential control, we plotted the voltage dependence of hNa v 1.5 activation and inactivation using VC (Fig. 1a) . At potentials ≤ −100 mV over 50% of hNa v 1.5 channels were de-inactivated and available (V 50 = −94.7 mV) and at potentials ≤ −135 mV all hNa v 1.5 channels were available. Membrane depolarizations above −65 mV activated a hNa v 1.5 current that maximized at depolarizations ≥ −25 mV (V 50 = −51.0 mV). We next co-transfected pcDNA3.1-ChR2-EYFP-βArchT and pSCN5A. Light induced ChR2 (−17.5 ± 8.3 pA/ pF at −80 mV) and ArchT current densities (1.8 ± 1.0 pA/pF at −40 mV) confirmed functional expression of both, ChR2 and ArchT, which was previously shown to be stoichiometric 13 ( Fig. 1c , Suppl. channels are inactivated (Fig. 1a) . By stepwise increasing the yellow light intensity, NG108 cells were increasingly hyperpolarized, reaching −98 ± 8.8 mV (N = 13) by maximal LED (595 nm, 37.4 mW/mm 2 ) and −112.4 ± 13 mV (N = 10) by laser (593.5 nm, 163 mW/mm 2 ) illumination ( Fig. 1d panel 1 ). The plateau of hyperpolarization at −112 mV defines the lower limit of the LiEp assay (V OPTOMIN ) and is a result of the ArchT activity approaching zero at −120 mV (Fig. 1c) . The maximum hNa v 1.5 action potential (AP) amplitude of +55 ± 2.0 mV (N = 9) was elicited by applying 2 ms blue light (473 nm) pulses with an intensity of ≥1.5 mW/mm 2 on maximal 163 mW/mm 2 595 nm background illumination (Fig. 1d, panel 2) . A de-inactivation curve of hNa v 1.5 currents was again plotted, this time from the blue-light induced hNa v 1.5 AP amplitudes recorded in current-clamp (CC) upon increasing levels of yellow background illumination. This "optical" curve (V 50 = −86.7 ± 1.0 mV, R 2 = 0.91, Boltzman fit; Fig. 1d panel 3 ) aligned well with the de-inactivation curve generated from VC data (Fig. 1a) , despite the known nonlinear relation of channel current and AP amplitude 22 (see Suppl. Fig. S1c and Suppl. Note 1). Consequently, hyperpolarization to −112 mV (corresponding to 163 mW/mm 2 595 nm illumination) sufficed to de-inactivate sufficient channels for a maximal blue-light induced hNa v 1.5 AP. These data demonstrate that hNa v 1.5 channel states can be modified by tuning the yellow light intensity. The reversal potential of the ChR2 peak current under 595/473 nm co-illumination was −28.5 mV (Fig. 1c) , defining V OPTOMAX of the LiEp interrogation window (Fig. 1a ) and lying well above the hNa v 1.5 activation threshold.
In summary, the light-tunable de-and hyperpolarization window of ChR2-EYFP-βArchT-expressing NG108-15 cells (~−112 mV to −28 mV) was sufficiently broad to effectively interrogate all hNa v 1.5 conformational states.
Optical and pharmacological hNa v 1.5 interrogation. To design an all-optogenetic LiEp assay, we implemented the archeorhodopsin-3 derived red-shifted genetic voltage indicator QuasAr1, shown to possess millisecond kinetics and small spectral overlap with ChR2 23 . We linked QuasAr1 N-terminally to the optogenetic tandem construct (QuasAr1-2A-ChR2-EYFP-βArchT) in order to achieve virtually "fixed" expression ratios of the three optogenetic tools. Since the QuasAr1 excitation spectrum almost completely overlaps with that of ArchT (Fig. 2a) we co-activated ArchT and QuasAr1 with the yellow laser and superimposed blue light pulses for ChR2 activation, triggering hNa v 1.5 activity (Fig. 2b) . This superimposed lighting protocol, although devoid of separable control of imaging and hyperpolarization, has the advantage that the ChR2 ground state is continuously re-populated, maximizing the ChR2 peak photocurrent under repeated illumination 24 (Suppl. Fig. S1b ). We first tested LiEp-based pharmacological screening of hNa v 1.5 with the use-dependent sodium channel blocker lidocaine 25 . We imaged the fluorescence changes of selected ChR2-ArchT-QuasAr1-expressing NG108 cells and concurrently patched one of the cells for CC recordings (Suppl. Fig. S2a ). At 2 Hz blue light activation, low-dose (300 μM) lidocaine cumulatively reduced the ΔF/F amplitude with increased block at higher (5 Hz) pacing frequencies, a hallmark of use-dependency (Fig. 2b) 8 we used a sequence of seven blue (2 ms) light pulses delivered at 5 Hz and averaged the last three hNa v 1.5 APs to ensure full hNa v 1.5 block (Suppl. Fig. S2a ). The QuasAr1 ∆F/F peak fluorescence decreased concomitantly with the hNa v 1.5 current amplitude in VC under increasing lidocaine concentrations (Fig. 2c) . The lidocaine block was fully reversible (washout 88.4 ± 6.3%, N = 14, p < 0.0001), was not apparent in cells that had not been co-transfected with pSCN5A (94.2 ± 6.0%, N = 6, p < 0.0001) and no block developed when the solvent DMSO was applied alone (95.0 ± 8.4%, N = 16 in 1% DMSO, p < 0.0001; Suppl. Fig. S2d ). Consequently, LiEp generated a large signal window with a Z' value of 0.542 (DMSO: 95.3 ± 3.4% vs. 10 mM lidocaine 51.4 ± 3.3%, N = 7 each, Fig. 2d ). To fit a Hill curve to the dose-response data, we determined the effective hNa v 1.5 activity by subtracting the underlying ChR2 ∆F/F value (53.1 ± 11.0%, N = 14) measured under saturating lidocaine concentrations (10 mM, Suppl. Figs S1c, S2d,e). The Hill curves for lidocaine action on hNa v 1.5 acquired with LiEp and VC were highly similar (Fig. 2c, Table 1 ). To confirm the validity of the LiEp protocol, we ensured signal stability under control conditions (DMSO) and evaluated two additional antiarrhythmic drugs, quinidine and flecainide. Also here the dose-response curves generated by LiEp and VC agreed well (Fig. 2c, Table 1 , Suppl. Note 1).
The tested drugs did not interact with the optogenetic proteins, apparent from a positive ∆F/F peak amplitude at full block (10 mM lidocaine: 0.09 ± 8.9% N = 9; 500 μM flecainide: 8.6 ± 10.8% N = 9; 300 μM quinidine: 12.9 ± 9.1% N = 10, mean ± s.e.m) and no change in baseline QuasAr1 fluorescence (normalized to F baseline in bath solution: 1% DMSO control 1.07 ± 0.15 N = 11, lidocaine 1.09 ± 0.11 N = 9, quinidine 1.12 ± 0.07 N = 10, flecainide 1.11 ± 0.10 N = 9; p = 0.705, one-way ANOVA). However, saturating quinidine concentrations, as described previously 26 , significantly reduced the amplitude of the ChR2 photocurrents (Suppl. Fig. S3 , Suppl. Table S1 ) but did not affect activation of hNa v 1.5, since the ChR2 photocurrent was still large enough.
In summary, bi-directional dynamic LiEp screening robustly and reliably reports drug interactions on hNa v 1.5 with comparable precision to parallel VC recordings.
LiEp on hERG. Due to the primary importance of hERG safety profiling we also designed a LiEp-hERG assay.
However, the high illumination intensity needed for QuasAr1 activation 23 as well as the dim QuasAr1 fluorescence (Suppl. Fig. S3 , Suppl. Table S2 ) are not compatible with present fluorescence plate readers. We therefore explored in the following the potential of the organic voltage-sensitive dyes Di-4-ANBDQPQ 27 and BeRST1 28 , which operate under significantly less light and give better signal-to-noise fluorescence ratios (Suppl. Fig. S3 , Suppl. Table S2 ). Another advantage of organic voltage indicators is their uniform targeting to the entire cell layer, enabling fluorescence readout across the whole field of view.
Imaging with Di-4-ANBDQPQ. We transiently introduced pcDNA3.1-KCNH2 encoding the alpha subunit of the human hERG channel into a stable optogenetic HEK293-ChR2(L132C) "CatCh" cell line 29 and measured the field of view compound response to a blue light pulse with the far-red voltage sensor Di-4-ANBDQPQ (λ max 603 nm, Fig. 3a ) 27 . We defined the voltage range of hERG activity by using standard voltage-step protocols 30 ,31 maximally applied drug concentration against 0.1% DMSO, *fit to normalized difference in negative peak membrane potential of hERG hyperpolarization and steady-state voltage as shown in Fig. 4a , $ values less sensitive than generally reported in literature 31, 57 , potentially due to different frequency of depolarization and shorter depolarization pulses.
Scientific REpORTS | (2018) 8:1153 | DOI:10.1038/s41598-018-19412-z (Fig. 3b) . Activation of the hERG tail current required a depolarization step above −30 mV, saturating at steps above +30 mV (N = 10). hERG currents reversed at around −80 mV. hERG expressing HEK293-CatCh cells had a resting membrane potential of −58.2 ± 6.4 mV (N = 14), defining V OPTOMIN, and CatCh stationary photocurrents reached −20.4 ± 8.6 mV (N = 8), defining V OPTOMAX ( Fig. 3b-d ). To optically mimic the depolarization step applied in VC protocols, we employed a 1 sec blue laser pulse (1 mW/mm 2 , Fig. 3d ) in CC. At the end of the light-triggered depolarization to −20 mV we observed a clear hyperpolarization before return to the resting membrane potential, which was abolished by the hERG blocker astemizole (30 μM). We subsequently used the light-triggered and resting membrane potentials as command voltages in a VC protocol to confirm the validity of the LiEp protocol (Fig. 3e ). We delivered a 1 sec depolarization step to −20 mV (V OPTOMAX ) followed by repolarization to −60 mV (V OPTOMIN ) that was able to produce a (non-saturated) hERG outward tail current. Controlled channel closure could be improved by using the optogenetic tandem actuator ChR2-βArchT combined with a spectrally separable voltage indicator, which is not given for Di-4-ANBDQPQ.
Next, we compared pharmacological data of the antiarrhythmic quinidine and the antihistaminics astemizole and terfenadine derived from VC, CC and LiEp side-by-side (Fig. 4a-c) . Blue light stimulation induced a substantial stimulus artifact in the Di-4-ANBDQPQ fluorescence signal and we therefore used the post-stimulus steady-state baseline fluorescence (after cessation of the hERG tail current) for trace alignment (Fig. 4a) . We applied ten consecutive blue light pulses and used the last ∆F/F value when a steady-state cumulative block was reached (Fig. 4b) . After each 10-pulse stimulation protocol the imaging location had to be changed due to Di-4-ANBDQPQ toxicity, obvious from granulation of somata and cell shrinkage. All drugs reliably blocked hERG in a concentration dependent manner and in good agreement with VC (Fig. 4c, Table 1 ). Drug application also depolarized the resting membrane potential, representative for a basal hERG conductance (10 μM astemizole −43.9 ± 5.2 mV, N = 5, p = 0.0003; Fig. 4a ). Imaging with BeRST1. Huang and colleagues (2016) recently designed a novel voltage-sensitive sulfonated-silicon-rhodamine-fluorophore-based dye, the Berkeley Red Sensor of Transmembrane potential (BeRST1) with a relatively narrow excitation spectrum and only 0.1% excitation at 473 nm 28 ( Fig. 5a ). We tested if BeRST1 may enable cross-talk free LiEp and may overcome the phototoxicity issue of Di-4-ANBDQPQ. hERG block for all drugs gave an excellent signal window (Z' ≥ 0. 66) and we detected no signs of phototoxicity allowing repeated data acquisition from the same imaging site. Compared to experiments with Di-4-ANBDQPQ, the CatCh mediated depolarization was resolved in the optical signal revealing the drug-induced membrane potential shifts analogously to CC (Fig. 5b) . In addition, Hill curve fits further approached those from VC (terfenadine: Hill slope −1.10, IC 50 Table 1 ).
Above data emphasizes the need for spectrally separable voltage sensors with better cell tolerability.
LiEp on hK v 1.5. We finally tested LiEp on the hK v 1.5 potassium channel, an important anti-arrhythmic drug target. In light of assay standardization we generated a monoclonal doxycycline inducible TetON-HEK2 93-ChR2(H134R)-EYFP-IRES-hK v 1.5 cell line, co-expressing the optogenetic actuator ChR2(H134R) with large stationary photocurrents 32 and the voltage-gated potassium channel hK v 1.5 (Fig. 6a ). The selected clone had a resting membrane potential of −45 ± 5.6 mV (N = 13; V OPTOMIN ). Additional optogenetic hyperpolarization was not required since hK v 1.5 does not exhibit a depolarization block. VC recordings on stable TetON-HEK293-Ch R2(H134R)-hK v 1.5 clones revealed a clear potassium current with an activation threshold at −40 mV that was reversibly blocked (91 ± 8%, N = 5, Fig. 6b ) by application of the open channel blocker and potential antiarrhythmic drug diphenylphosphine oxide (DPO-1, 0.3 μM) 33 . Under full hK v 1.5 block the ChR2(H134R) steady-state reversal potential was at −7 mV (V OPTOMAX ). We first performed blue light hK v 1.5 actuation in CC to evaluate the readout signal. The ChR2(H134R) depolarizing current induced a secondary hyperpolarizing hK v 1.5 current, which decreased the steady-state ChR2(H134R) depolarization by 20.56 ± 4.56 mV (N = 13, Fig. 6c ). Besides the reduced steady-state amplitude of the light-induced voltage step, hK v 1.5 channel activity was evident from the quick recovery of the light-induced ChR2 depolarization resulting in a sharp transient at "light on" as well as the hK v 1.5 induced hyperpolarization at "light off " (Fig. 6c ). To further demonstrate the tractability of LiEp, we explored yet another fast organic voltage sensor, RH421 34 ( Fig. 6a) . Due to the significant spectral overlap of the activation spectra of RH421 and ChR2(H134R) we activated RH421 with narrow-band (565/24) green light at the red absorption flank that was too low in intensity (<0.01 mW mm −2 ) to significantly activate ChR2(H134R) (Fig. 6a) . Since DPO-1 is an open channel blocker, we applied 1 second long 473 nm light pulses in imaging experiments and only analyzed the final 100 ms of RH421 fluorescence acquisition when a full block had developed (Suppl. Fig. S4) . The recorded RH421 signal from the TetON-HEK293-ChR2(H134R)-hK v 1.5 cell layer in response to DPO-1 application changed analogously to CC (Fig. 6d) (Fig. 6e) . Comparing data against recordings from untransfected HEK-ChR2-YFP cells allowed us to exclude unspecific DPO-1 effects on ChR2. We next applied LiEp to pharmacological characterization of DPO-1 and compared the concentration-response curves generated by VC and LiEp side-by-side using a 0.5 Hz stimulation protocol. The two concentration-response curves were highly similar ( 
Discussion
LiEp is the first all-optical method meeting the temporal precision and dynamic transmembrane potential control required for high-content pharmacological drug characterization on VGCs and distinguishes itself from previously proposed optical methodologies 23, [37] [38] [39] [40] [41] by bi-directional optogenetic membrane potential control 13 . We demonstrated the tractability and reproducibility of LiEp by exchanging optogenetic actuators and voltage sensors to optically investigate the activity of various VGCs.
Our study focused on demonstrating the potential impact of optical drug screening rather than on new electrophysiological insights or novel drug evaluation. In these terms, LiEp produced excellent screening signal windows with Z′ values above 0.5, enabled optical detection of use-dependency, which had previously been demonstrated by other groups using optical protocols 11, 38, 40 and closely reproduced IC 50 and Hill coefficient values from parallel VC recordings, i.e. within 1 log unit or 1-4 fold difference, respectively, ranges well accepted in automated electrophysiology assays 42 . The small, yet systematic IC 50 discrepancies between VC and LiEp measurements on hNa v 1.5 channels arise from the known non-linear relation of channel current and membrane potential amplitude (see also Suppl. Note 1). The accuracy of the LiEp assay is remarkable given that, in contrast to the virtually unlimited signal amplitude of ionic channel currents in VC, a closed-loop circuit as is needed for a "true clamp" is not in place in LiEp. Optogenetic tools possess complex photocurrent kinetics and are unable to counteract the fast gating and high conductivity of VGCs. In addition the membrane capacitance also influences the voltage changes. The unclamped membrane potential, and hence the optical readout, is consequently restrained by the optogenetic reversal and ionic equilibrium potentials as well as the imaging light intensities. One interesting prospect of our study is that LiEp may ease measurements of fast Na v channels at physiological temperature, which is highly challenging in VC since compensatory feedback is prone to "self-clamping" of the channel-expressing cell.
One drawback of optical compared to electric interrogation is, however, the difficulty to relate light-step protocols to well-defined potential-step protocols, which are ultimately needed for accurate VGC probing. A stable optogenetic cell line could, in principle, allow the experimenter to directly assign light intensity at a given wavelength to transmembrane voltage, by relating the reversal or resting membrane potentials to particular fluorescence values on the voltage sensor's (linear) calibration curves (see Fig. 5b, Suppl. Fig. S5) .
Optimally LiEp will be performed by 3D orthogonal optical stimulation, using a blue-light activated channelrhodopsin, a yellow light-activated ArchT and far-red activated voltage sensor with fully separable activation spectra. In our initial LiEp assays the spectral crosstalk of QuasAr1 with ArchT reduced the sensitivity of hNa v 1.5 to lidocaine compared to literature values 8 since the cells were depolarized to the resting membrane potential in the inter-imaging intervals when the yellow laser was turned off. This modified the lidocaine binding kinetics 43 . A genetic voltage indicator such as QuasAr1 has the ability to be stably integrated into a cell line, which would simplify the screening assay and reduce costs. Other non-pumping near infrared fluorescing Arch-variants have been created by directed evolution but have not yet been evaluated as voltage sensors 44, 45 . One problem with QuasArs is their extreme light requirements that lie 3-4 log units above the maximum light intensities in currently available plate readers, making customized platforms necessary. In contrast, the ChR2(D156A) variant with similar light-sensitivity to the here used CatCh has already been successfully actuated in a FLIPR tetra ® reader (Molecular devices) for optogenetic Ca v channel drug screening with Ca 2+ sensor (Fluo-8) readout 39 . The very slow off-kinetics of ChR2(D156A) 24 , however, are not suited for screening of rapidly-gated VGCs such as hNa v 1.5, but CatCh could be used instead. And voltage sensors are generally less sensitive than Ca 2+ indicators. The development of spectrally separable and light-sensitive voltage sensors with fast temporal resolution will facilitate the adaptation of LiEp in a plate reader format.
For the LiEp platform to be reliable, compounds should not significantly interfere with the functionality of the optogenetic actuators or sensors. As reported previously by others 38, 40 we found no dramatic drug effects on the photocurrent amplitudes or kinetics of the employed optogenetic tools nor did the drugs affect the baseline fluorescence of the voltage sensors (Suppl. Fig. S3 , Suppl. Table 1 ). One exception was quinidine, which, if applied at saturating doses, significantly reduced the ChR2 photocurrents in line with previous reports of photocurrent inhibition in C. reinhardii that endogenously expresses ChR2 and other opsins 26 . The quality of the LiEp assay remained, however, unaffected. A drug-channel interaction is easily detected in the LiEp assay when the ΔF/F signal falls below the ChR2 ΔF/F value (see Suppl. Fig. S2 ).
Present optical VGC screening techniques typically manipulate the membrane potential artificially, by increasing extracellular potassium to depolarize the cells 46 and introducing a rectified potassium leak current, usually through Kir2.1, to hyperpolarize the cells 37, 38, 47 . Kir 2.1 modulates cell growth 48 and is a CiPA safety target potentially susceptible to drug interactions 49 . Solution exchange decreases the assay's temporal resolution and a changing extracellular ion composition can affect channel gating through selectivity filter interactions 50 . For all above reasons optogenetic membrane potential toggling through ArchT proton pumping and ChR2 cation conductance is a major advantage and enables contact-free, millisecond VGC interrogation under physiological conditions. The main advantages of LiEp over commercially applied fluorescence assays such as FLIPR 12,51,52 and VIPR 10, 46 or the combined optical-electric E-VIPR 11 are (i) the millisecond activation, deactivation and readout kinetics on the timescale of VC enabling the induction and study of transient and rapidly inactivating channels, (ii) the ability to run calibrated light-step protocols to differentially interrogate VGC conformational states and (iii) the possibility for repetitive stimulation to study use-dependency. Although plate readers are yet unable to deliver millisecond-switchable multi-wavelength excitation and possess readout latencies typically incompatible with fast-acting VGCs, the scalability of all-optical optogenetic assays has been shown using microscope-based platforms carrying high aperture optics combined with movable stages holding multi-well plates 38, 40 . In summary, we have shown that LiEp is a simple, fast and versatile technique fulfilling crucial criteria for adaptation into a high-throughput screening platform 53 . We showed that LiEp is compatible with a palette of VGCs, optogenetic actuators, voltage sensors and cell lines and in combination with suitable optical hardware may pose an alternative to complicated and costly electrophysiological platforms for future high-throughput screening. In particular, LiEp may enable large scale early phase VGC isoform specific profiling and can complement the recently proposed optical iPSC cardiomyocyte technologies in the framework of the CiPA initiative 40, 41 .
Methods
Plasmids and molecular biology. Expression was in all constructs driven by the cytomegalovirus (CMV) promoter. pcDNA3.1-SCN5A (pSCN5A) encoding the alpha subunit of the human hNa v 1.5 channel was a kind gift from Bela Kelety (IonGate GmbH). pcDNA3.1-KCNH2 encoding the alpha subunit of the human hERG (K v 11.1) channel was a kind gift from Hugues Abriel (University of Bern). The light-driven chloride pump NpHR from pcDNA3.1-ChR2-EYFP-βNphR 13 was replaced by the light-driven proton pump ArchT 15 (kindly supplied by Ed Boyden, MIT) to construct the vector pcDNA3.1-ChR2-EYFP-βArchT. QuasAr1-mOrange-P2A was amplified from FCK-Optopatch1 23 (Addgene: 51695; F: 5′-CTATGGATCCACCA-TGGTAAGTATCGCT-3′, R: 5′-CTATGGATCCGGGACCGGGGTTTTCTTCCA-3′) and inserted in front of ChR2 in pcDNA3.1-ChR2-EYFP-βArchT using the BamHI restriction site, resulting in pcDNA3.1-QuasAr1-mOrange2-P2A-ChR2-EYFPβArchT. EYFP served in all constructs for the visualization of successful expression in the receptive cell lines. VGC plasmids without EYFP were co-transfected with optogenetic EYFP-labeled constructs to identifiy transfected cells.
Cell lines and culture conditions. Using effectene transfection (QIAGEN, Hilden, Germany) a stable inducible HEK293 cell line (TetON-HEK293-ChR2(H134R)-EYFP-IRES-hK v 1.5) was created that doxycycline dependently co-expressed ChR2(H134R)-EYFP and hK v 1.5 from an internal ribosome entry site (IRES) using Clontech's Tet-On 3 G system (Clontech, Saint-Germain-en-Laye, France). Undifferentiated NG108-15 neuroblastoma (ATCC ® HB-12317 TM ) and HEK293 (ATCC ® CRL-1573 TM ) cells were cultured in Dulbecco's Modified Eagle Medium (Sigma Aldrich) supplemented with 10% fetal calf serum (FCS), 10 U/ml penicillin, 100 µg/ml streptomycin and 1 mM L-Glutamin (Millipore) at 37 °C with 5% CO 2 . HEK-CatCh cells 29 were maintained under neomycin (750 μg/ml, Promega) selection, the TetON-HEK293-ChR2-hK v 1.5 cell line under combined neomycin (800 μg/ml, Promega) and hygromycin (600 μg/ml, Sigma) selection.
For hNa v 1.5 experiments, 1.6 × 10 5 NG108-15 cells were plated on poly-L-ornithine (Sigma Aldrich) coated 22 mm glass coverslips in 12 well plates. pcDNA3.1-ChR2-EYFP-βArchT or pcDNA3.1-QuasAr1-mOrange2-P2 A-ChR2-EYFP-βArchT were co-transfected with pcDNA3.1-SCN5A at a 2:3 molar ratio, using the Lipofectamin 2000 transfection kit (Life Technologies). For hERG experiments, 4 × 10 6 HEK293-Catch cells 29 were plated in a 10 cm diameter culture plate and transfected with pcDNA3.1-KCNH2 using calcium phosphate precipitation 54 Voltage-clamp step protocols are given in suppl. Fig. S6 . Whole-cell current-clamp (CC) experiments were performed with 0 pA holding currents. For ChR2-EYFP-ArchT light tuning curves (Fig. 1d) , a tunable pE-4000 LED system (CoolLED Ltd. Andover UK) and a 593.5 nm shutter controlled diode-pumped solid state laser (Pusch Opto Tech GmbH) were used. τ ON and τ OFF values were determined with a single exponential fit (Chebyshev method) in Clampfit:
ChR2 current-voltage relationships were fitted with second and third order polynomial functions (extra sum-of-squares F test, simpler model selected if p > 0.05) and the best fit chosen for calculation of the reversal potential for f(x) = 0.
LiEp activation, imaging processing and data analysis. All experiments were conducted at room temperature. For optogenetic activation we used either diode-pumped solid-state (DPSS), shutter-controlled (Uniblitz LS6ZM2, Vincent Associates) 473 nm and 593.5 nm lasers (Pusch Opto Tech GmbH) focused into optic fibers (Thorlabs), whereas the 473 nm laser was mainly used for channelrhodopsin activation and focused into a 400 μm diameter optic fiber the tip of which was directly placed into the bath proximal to the cells. Alternatively we used a tunable LED array (pE-4000, CoolLED Ltd. Andover UK) connected to the fluorescence port of the microscope. Details about the imaging settings such as light intensities, wavelengths and detectors are given in Table 2 .
hK v 1.5 -RH421. HEK293-ChR2(H134R) cells on coverslips were incubated in 5 μM RH421 (N-(4-Sulfobutyl)-4-(4-(p-(dipentylamino)phenyl)butadienyl)-pyridinium inner salt; Life Technologies) 34 for 10 min in the dark, followed by a brief wash in bath solution and transferred into a perfusion chamber mounted on a fluorescence upright Zeiss Axioskop 2FS microscope (Zeiss) equipped with a 40× water immersion objective (numerical aperture = 0.8; Fig. 6a ). Fluorescence was excited by a 100-W tungsten lamp using a 565DF24 excitation filter, a 630DF69 emission filter, and a 585DRLP dichroic mirror (AF Analysentechnik, Tübingen, Germany) and whole-field fluorescence detected with a PIN-022A photodiode (United Detector Technologies, Brignoles, France) mounted to the microscope camera port (Fig. 6a) . 473 nm light was passed through a heat absorption filter (KG filter, Schott), which removed long-wavelength stray light that increases background noise at the photodiode. Photodiode signals were amplified by a variable-gain low-noise current amplifier (Model DLPCA-200, FEMTO Messtechnik), digitized at 2 kHz with an Axon Digidata 1200 and acquired and analyzed using pClamp9 software (Axon Instruments).
Optical traces were started 5 s before and stopped 5 s after 473 nm laser pulses. The 473 nm stimulation artifacts were removed and the baseline corrected for RH421 bleaching by linear baseline subtraction in OriginLab software and the raw fluorescence trace inverted (Suppl. Fig. S4 ). The light-induced fluorescence changes were normalized to F baseline immediately before the laser onset that remained consistent upon addition of the inhibitor DPO-1. The last 3 of 6 laser stimulation events paced at 0.5 Hz were averaged for analysis of DPO-1 inhibition. Only the stationary fluorescence values at the end of the ChR2(H134R) activation ("evaluation window" Suppl. Fig. S4 ) were used to determine the ∆F/F values For optical dose-response experiments with DPO-1 we normalized the change in fluorescence (ΔF x ) to the fluorescence change at maximal drug effect (∆F max ): Fig. S2a ). Only cells with a ∆F/F change ≥5% upon 473 nm light illumination were included into the analysis. The baseline fluorescence (F) was defined to a 50 ms window 200 ms after the start of the 593.5 nm laser illumination. The last three ∆F/F peaks triggered by 473 nm laser pulses (2 ms) at 5 Hz were averaged and the laser artifact removed from the signal by setting the averaged ∆F/F during 473 nm illuminations to 0 (Suppl. Fig. S2b ). Non-specific response rundown between measurements when acquiring dose-response curves was corrected by automated exponential baseline subtraction in Clampfit:
plateau Kx plateau 0 with y 0 = 1, y plateau = 0.8297, K = 0.5516 and x being the number of measurements within the series as observed under control conditions (Suppl. Fig. S3d ). The fractional contribution of the ChR2 peak to the ∆F/F signal (ChR2 baseline ) was determined as the mean 473 nm light-induced peak ∆F/F signal under full lidocaine block (10 mM) and subtracted to isolate the hNa v 1.5 induced ∆F/F value (ChR2 baseline with rundown compensation of x = 1).
hERG -Di-4-ANBDQPQ. Cells were loaded with 20 μM Di-4-ANBDQPQ (kind gift from Leslie Loew, University of Connecticut) 27 for 5 min before being placed into fresh bath solution for experiments. ChR2(L132C) was activated by 1 second long 473 nm light pulses (1 mW/mm 2 at cells). The light from the 635 nm LED of the pE-4000 was passed through a 630/30 nm excitation filter and reflected by a 650 nm dichroic mirror (output at cells 5 mW/mm 2 ). Emitted Di-4-ANBDQPQ fluorescence was passed through a 665 nm LP filter and imaged at 125 Hz by the RedShirt NeuroCCD camera with 80 × 80 pixels resolution. For each trace recorded, the field of view was moved to minimize the effect of local photodamage. The full field optical signal was spatially averaged to a single trace for analysis and inverted. The baseline fluorescence (F) was defined to a 300 ms time window 340 ms after imaging light onset. Bleaching was corrected by automated exponential baseline subtraction in Clampfit in each trace. For the quantification of drug action on hERG, the traces were aligned to the mean steady state fluorescence in a 1 second time window from 2.5 to 3.5 seconds after the offset of the 473 nm laser (Fig. 4a) . Channel activity was quantified by the negative peak value of the ∆F/F signal in a time window of 1 s after the 473 nm light offset (Fig. 4a). hERG-BeRST1. Cells were loaded with 1 μM BeRST1 28 (kind gift from Evan Miller, University of California) for 10 min. hERG experiments with the dye BeRST1 were performed with identical light sources, filters and settings as for Di-4-ANBDQPQ except that the 635 nm LED was increased to 20 mW/mm 2 and the imaging frame rate was reduced to 40 Hz. Dose-response quantification was performed as described for Di-4-ANBDQPQ (Fig. 4a) .
General data analysis. All dose-response curves were fitted with a Hill function and IC 50 ± standard error 
All data are indicated as mean ± standard deviation (s.d.) in the main text and as mean ± standard error of the mean (s.e.m.) in figures if not stated otherwise. Offline analysis was performed in Excel, Clampfit, OriginLab and GraphPad Prism. P-values in figures are indicated as follows: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
